

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**MTA Abatacept, adalimumab, etanercept and tocilizumab  
for treating juvenile idiopathic arthritis (including review of  
TA35) [ID783]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Final Appraisal Determination**

(when no ACD was issued)

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

The Committee noted that, during scoping, a consultee raised that the recommendations in TA 35 could be interpreted that people over the age of 17 should not receive etanercept. The Committee recognised that the marketing authorisation at the time of TA35 specified the age range 4-17 but the marketing authorisation has now been updated and does not specify a maximum age for eligibility for etanercept. The Committee considered that the technologies should be used within the age-range specified in the marketing authorisation for each technology and that its recommendations did not restrict access on the basis of age.
--

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No.
-----

- |  |
|--|
| 3. Have any other potential equality issues been identified by the |
|--|

Committee, and, if so, how has the Committee addressed these?
No.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
Not applicable

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
Not applicable

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable

7. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Not applicable

**Approved by Programme Director (name):** Meindert Boysen

**Date:** 27/10/2015

